Welcome to our dedicated page for VAPOTHERM news (Ticker: VAPO), a resource for investors and traders seeking the latest updates and insights on VAPOTHERM stock.
Vapotherm, Inc. (OTCQX: VAPO) is a leading developer and manufacturer of advanced respiratory technology headquartered in Exeter, New Hampshire, USA. The company focuses on creating innovative, comfortable, and non-invasive technologies to support patients with chronic or acute breathing disorders. Over 4.4 million patients globally have benefited from Vapotherm's high-velocity therapy systems, including the HVT 2.0 and Precision Flow systems.
Vapotherm's core product, high-velocity therapy, is a mask-free, non-invasive ventilatory support tool that effectively relieves respiratory distress—including hypercapnia, hypoxemia, and dyspnea. This technology allows for the fast, safe treatment of undifferentiated respiratory distress with a single tool. The mask-free interface delivers optimally conditioned breathing gases, making it more comfortable for patients and reducing the risks associated with traditional mask therapies.
The company has shown significant sales growth and continues to invest in future growth drivers such as the HVT 2.0, clinical studies, and the upcoming Access365™ Home Ventilation Solution, anticipated to launch in early 2025. This new home ventilation solution aims to improve patient quality of life and reduce hospital readmissions for patients with respiratory diseases.
Financially, Vapotherm has made considerable strides in improving profitability. For example, in the third quarter of 2023, the company reported a net revenue increase of 12.0% over the previous year, attributed to rising capital and disposable demand, especially in international markets. Furthermore, gross profit and margin saw improvements, owing to effective inventory management and increased production efficiencies.
Despite challenges, such as delisting from the New York Stock Exchange and transitioning to the OTCQX Market, the company remains steadfast in its commitment to enhancing patient lives and maintaining significant market presence. Partnerships like the one with Onymos to develop a respiratory digital platform further underscore Vapotherm's dedication to innovation and improved patient outcomes.
Vapotherm, Inc. (NYSE: VAPO) will release its third quarter 2022 financial results on November 2, 2022, after market close. A conference call is scheduled for 4:30 p.m. ET to discuss the results and business updates. Vapotherm specializes in high velocity therapy products for respiratory distress treatment. The company has provided non-invasive solutions for over 3.5 million patients, emphasizing comfort and ease of use during therapy.
Vapotherm, Inc. (NYSE: VAPO) announced on September 30, 2022, an Amendment to its Loan and Security Agreement, adjusting its minimum revenue and liquidity covenants. The company was also notified on September 27, 2022, by the NYSE for non-compliance with listing standards due to an average market capitalization of approximately $48.8 million and stockholders' equity of about $13.7 million. Vapotherm plans to submit a compliance plan to the NYSE within 45 days. The company continues to operate as normal and will maintain its stock listing under VAPO, marked as “.BC.”
Vapotherm, Inc. (NYSE: VAPO), a medical technology company specializing in respiratory support technologies, will present at the Canaccord Genuity 42nd Annual Growth Conference on August 11, 2022, at 11:00 am Eastern Time. The presentation will be accessible via a live webcast. Vapotherm's high velocity therapy® systems have treated over 3.5 million patients, providing mask-free, non-invasive ventilatory support. For more details, the webcast replay will be available for 90 days on Vapotherm's Investor website.
Vapotherm (NYSE: VAPO) reported Q2 2022 revenue of $13 million, a 37.1% decline year-over-year, driven by decreased respiratory patient census and customer destocking. Disposables revenue fell 38.2% to $7.9 million. Despite a sequential recovery in May and June, gross profit was $2.4 million with an 18.2% margin. The company faced a net loss of $42.7 million, or $1.61 per share, influenced by an $18.7 million goodwill impairment. For FY 2022, guidance is set at $76-81 million revenue, with an expected gross margin of 30-32%. Management aims for adjusted EBITDA positivity by Q4 2023.
Vapotherm, a medical technology firm, will announce its financial results for Q2 2022 on August 3, 2022, after market close. A conference call to discuss results and business updates will occur at 4:30 p.m. ET. Vapotherm specializes in high velocity therapy products aiding patients with respiratory distress. The company has treated over 3.5 million patients with its non-invasive therapies, enhancing comfort and efficacy in respiratory care.
Vapotherm, Inc. (NYSE: VAPO), a leader in advanced respiratory technology, will participate in the William Blair 42nd Annual Growth Stock Conference on June 6, 2022, at 1:40 PM ET. The management team will present and the session can be accessed via a live webcast. Vapotherm's innovative high velocity therapy® products provide non-invasive respiratory support, effectively treating over 3.5 million patients with conditions like hypercapnia and hypoxemia. A recording of the presentation will be available for 90 days after the event on their Investor website.
Vapotherm reported first-quarter 2022 revenue of $21.6 million, a 33.1% decrease compared to the same quarter in 2021. Disposables revenue fell by 13.3% to $14.9 million. The company noted lower patient census for respiratory illnesses and COVID-19-related hospitalizations. Gross profit was $7.9 million, with a gross margin of 36.6%. Operating expenses increased by $0.9 million year-over-year to $27.8 million. The net loss for the quarter was $22.9 million, or $0.87 per share. The company reinstated revenue guidance for fiscal 2022, projecting $81 million to $86 million.
Vapotherm, Inc. (NYSE: VAPO) announced it will release its financial results for Q1 2022 on May 4, 2022, after market close. A conference call will follow at 4:30 p.m. ET to discuss results and business developments. Vapotherm specializes in high-velocity therapy for respiratory distress, having treated over 3.2 million patients. Interested parties can access the call via telephone or through a live webcast on the company's investor relations website, with a replay available until May 11, 2022.
Vapotherm, Inc. (NYSE: VAPO) announced preliminary first quarter 2022 revenue estimates between $20.5 million to $21.5 million, down from $32.3 million in Q1 2021. The company has withdrawn its full-year 2022 revenue guidance due to reduced COVID-19 hospitalizations and a decline in flu and RSV cases. CEO Joe Army noted a significant slowdown in hospitalizations in March, prompting the reevaluation of earlier projections. The finalized results will be disclosed on May 4, 2022, along with a conference call to discuss financial outcomes.
Vapotherm, Inc. (NYSE: VAPO) has announced a strategic partnership with Carnegie Mellon University to implement an artificial intelligence (AI) training program named Vapotherm AI for Business. This initiative aims to enhance AI skills among Vapotherm employees, improving customer care and reducing healthcare costs related to chronic respiratory diseases. The program, developed by Carnegie Mellon’s Tepper School of Business, will commence in early March 2022, leveraging the university's expertise to integrate AI into Vapotherm's product offerings.
FAQ
What is the current stock price of VAPOTHERM (VAPO)?
What is the market cap of VAPOTHERM (VAPO)?
What does Vapotherm, Inc. specialize in?
What are Vapotherm's core products?
How many patients have been treated with Vapotherm's technology?
Where is Vapotherm headquartered?
What financial progress has Vapotherm made recently?
What is Vapotherm's Access365 Home Ventilation Solution?
What challenges has Vapotherm faced recently?
What recent partnerships has Vapotherm formed?
What upcoming product launches does Vapotherm have?
How does Vapotherm's high-velocity therapy benefit patients?
